🇺🇸 AdreView in United States

FDA authorised AdreView on 19 September 2008 · 94 US adverse-event reports

Marketing authorisation

FDA — authorised 19 September 2008

  • Application: NDA022290
  • Marketing authorisation holder: GE HEALTHCARE
  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. No Adverse Event — 40 reports (42.55%)
  2. Radioisotope Scan Abnormal — 19 reports (20.21%)
  3. Drug Ineffective — 18 reports (19.15%)
  4. Fatigue — 4 reports (4.26%)
  5. False Positive Investigation Result — 3 reports (3.19%)
  6. Burning Sensation — 2 reports (2.13%)
  7. Dizziness — 2 reports (2.13%)
  8. Product Quality Issue — 2 reports (2.13%)
  9. Rash Erythematous — 2 reports (2.13%)
  10. Syncope — 2 reports (2.13%)

Source database →

Other Cardiovascular approved in United States

Frequently asked questions

Is AdreView approved in United States?

Yes. FDA authorised it on 19 September 2008.

Who is the marketing authorisation holder for AdreView in United States?

GE HEALTHCARE holds the US marketing authorisation.